heterodimers

Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) is an IgG1 antibody inhibitor derived from mice, specifically targeting rat FcRn heavy chain heterodimers.

Anti-RatFcRnheavy chain heterodimers Antibody (1G3) is a mouse-derived antibody, specifically targeting the FcRn heavy chain heterodimers. The isotype control for Anti-RatFcRnheavy chain heterodimers Antibody (1G3) is designated as MouseIgG1kappa, Isotype Control.

2,2′-Dipyridyl disulfide (Aldrithiol 2) is a useful reagent for the determination of sulfhydryl groups. It acts as a peptide coupling reagent and as an oxidizing agent. 2,2′-Dipyridyl disulfide (Aldrithiol 2) is also used for the activation of glycosides.

EMD57033 is a cardiac troponin C (cTnC) activator, a dominant Ca2+ sensitizer, which functions by binding to cardiac/slow skeletal troponin C heterodimers to promote cardiac contraction.

TWIK-1/TREK-1-IN-3 is a selective and potent inhibitor of the potassium channel TREK-1, effectively inhibiting TREK-1 homodimers and TWIK-1/TREK-1 heterodimers containing two-pore-domain potassium (K2p) channels. TWIK-1/TREK-1-IN-3 exhibits antidepressant activity and can be utilized in the study of depression.

LG100754 (UVI 2112) is an insulin sensitizer that functions through RXR. LG100754 is an RXR dimer modulator. LG100754 acts as an RXR: RXR homodimer antagonist, but functions as an agonist towards RXR: PPARα and RXR: PPARγ heterodimers.

sAJM589 is a Myc inhibitor that dose-dependently disrupts Myc-Max heterodimers, thereby decreasing Myc protein levels. Myc is a multifunctional nuclear phosphoprotein that plays a key role in cell cycle progression, apoptosis, and cellular transformation. sAJM589 inhibits the cellular proliferation of a variety of Myc-dependent cancer cell lines and the adherent, non-dependent growth of Raji cells’ Growth.

Nurr1 agonist 9 (Compound 36) acts as an agonist for Nurr1, with an EC50 of 0.090 µM and a Kd of 0.17 µM. It activates Nurr1 homodimers (NurRE, EC50 = 0.094 µM) and Nurr1-RXR heterodimers (DR5, EC50 = 0.165 µM). This compound induces the expression of Nurr1-regulated tyrosine hydroxylase (TH) in Parkinson's disease organoid models and can penetrate the human brain endothelial cell barrier.

Nurr1/RXR dual agonist 1 is a dual activator of Nurr1 (EC50 = 2.6 µM) and RXR, with Ks values of 0.6 and 1.1 µM, respectively. It disrupts the stability of Nurr1 homodimers selectively while stabilizing Nurr1:RXR heterodimers, specifically activating the heterodimer response element DR5. In neuronal cells, Nurr1/RXR dual agonist 1 enhances the expression of neuroprotective Nurr1 target genes without inducing genes associated with off-target effects. This compound is applicable in studies related to neurodegenerative diseases.

Pegpleranib sodium is a polyethylene glycol-modified nucleic acid aptamer that specifically binds to the homodimers and heterodimers of PDGF-BB and PDGF-AB, thereby inhibiting their interaction with associated tyrosine kinase receptors.

Pegpleranib is a polyethylene glycol-modified nucleic acid aptamer that specifically binds to both homodimers and heterodimers of PDGF-BB and PDGF-AB, thereby inhibiting their interaction with associated tyrosine kinase receptors.

HX-603 is a selectivity agonist of RXR that inhibits the activation of RAR-RXR heterodimers as well as RXR homodimers.

SN52 is a powerful, competitive, and cell-permeable inhibitor of NF-κB2. It is a variant of the SN50 peptide. SN52 effectively prevents the nuclear translocation of p52-RelB heterodimers, exhibiting a robust radiosensitization effect on prostate cancer cells. This compound holds significant potential for cancer research purposes.

3-(3-Phenoxybenzyl)amino-β-carboline is a highly effective tubulin inhibitor, selectively degrading αβ-tubulin heterodimers, inducing cell cycle arrest and apoptosis in the G2/M phase, and displaying notable anticancer activity [1].

Izalontamab (SI-B001) is a bispecific EGFR/HER3 monoclonal antibody that binds to both EGFR×EGFR homodimers and EGFR×HER3 heterodimers, thereby blocking downstream pathways. It is applicable for locally advanced or metastatic epithelial tumours, such as non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).

Compound 2a, identified as TWIK-1/TREK-1-IN-1, acts as an inhibitor of the TREK-1, a two-pore domain potassium channel (K2p) that forms TREK-1 homodimers and TWIK-1/TREK-1 heterodimers, both significant for its role as an antidepressant target. Furthermore, TWIK-1/TREK-1-IN-3, a related compound, selectively inhibits these channels with IC50 values of 9.36 μM for TREK-1 homodimers and 14.6 μM for TWIK-1/TREK-1 heterodimers, demonstrating antidepressant-like effects [1].

JY-3-094 is a selective Myc inhibitor that targets the hydrophobic domain of Myc and inhibits the formation of the Myc-Max heterodimer, with an IC50 of 33 μM, and can be used for cancer research.

αvβ5 integrin-IN-2 (Cpd_AV2) is an inhibitor that targets the β-propeller central pocket of ITGAV (integrin αV) and disrupts the stability of integrin heterodimers. This compound induces cellular apoptosis [1].

TAT-D1 peptide is a selective D1-D2 heteromer antagonist. It disrupts D1-D2 receptor heterodimers by interacting with specific domains of the D2 receptor through its unique amino acid sequence, especially the two glutamic acid residues at the C-terminus of the D1 receptor. TAT-D1 peptide is used for studying the role of D1-D2 receptor heterodimers in regulating depression and anxiety-like behaviors.

Mal-PEG-NHS ester (MW 2000) is a PEG linker utilized in conjugating lipoteichoic acid (LTA) with CpG DNA fragments to synthesize CpG-TA heterodimers. It is applicable in immune stimulation research.